BioFarma Innovations will be based in the United Kingdom and its president will be David Triesman, who worked with the National Health Service for over 40 years.
“Our mission is to prioritize public health. We are offering a dynamic and open approach to collaborate with global pharmaceutical companies and public health organizations in Europe and the British Commonwealth. It ranges from license assignments to R&D agreements,” BioCubaFarma chairman Eduardo Martinez said.
"We have consolidated a broad portfolio of products and we want to guarantee access to new drugs to help meet worldwide unmet demands," he stressed.